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Abstract
We observed prominent effects of doxorubicin (Dox), an anthracycline widely used in anti-
cancer therapy, on the aggregation and intracellular distribution of both partners of the H2A-
H2B dimer, with marked differences between the two histones. Histone aggregation,
assessed by Laser Scanning Cytometry via the retention of the aggregates in isolated
nuclei, was observed in the case of H2A. The dominant effect of the anthracycline on H2B
was its massive accumulation in the cytoplasm of the Jurkat leukemia cells concomitant
with its disappearance from the nuclei, detected by confocal microscopy and mass spec-
trometry. A similar effect of the anthracycline was observed in primary human lymphoid
cells, and also in monocyte-derived dendritic cells that harbor an unusually high amount of
H2B in their cytoplasm even in the absence of Dox treatment. The nucleo-cytoplasmic trans-
location of H2B was not affected by inhibitors of major biochemical pathways or the nuclear
export inhibitor leptomycin B, but it was completely diminished by PYR-41, an inhibitor with
pleiotropic effects on protein degradation pathways. Dox and PYR-41 acted synergistically
according to isobologram analyses of cytotoxicity. These large-scale effects were detected
already at Dox concentrations that may be reached in the typical clinical settings, therefore
they can contribute both to the anti-cancer mechanism and to the side-effects of this
anthracycline.
Introduction
Doxorubicin (Dox; also known as Adriamycin) is a widely used anthracycline anticancer drug
which is applied in the treatment of various forms of leukemia and solid tumors, including T
and B cell leukaemias, Hodgkin’s lymphoma, tumors of the bladder, breast, stomach and the
lungs [1]. Overcoming its most common side effects, cardiotoxicity and treatment-related leu-
kaemias, is a major challenge; both are rather specific for anthracyclines [2].
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Dox is a pleiotropic drug having multiple targets. The main mechanisms of action include
cell cycle block by topoisomerase II inhibition [3], inhibition of DNA and RNA synthesis [4],
increased production of intracellular reactive oxygen species [5], and reorganization of F-actin
[6]. Dox was shown to induce autophagy [7] and also to cause its dysregulation by inhibition
of lysosomal acidification [8].
The DNA and/or chromatin-related effects may be explained by multitudes of molecular
interactions: Anthracyclines intercalate between the neighboring base-pairs of the double-
helix [9], bind free histones [10], can form anthracycline-DNA covalent adducts [11] and are
able to destabilize G-quadruplex structures [12]. Intercalation is accompanied by the release of
histones and eventually with eviction of the complete nucleosome [13–15]. All this is not sur-
prising considering that it relaxes the natural twist of the DNA double helix by −27˚/ interca-
lating molecule [16]. Intercalation also changes the DNA length and rigidity [17] and increases
the melting point of the double-helix [18].
Anthracycline-induced nucleosome eviction is accompanied by de-repression of many
genes [13] and by the generation of double-strand DNA breaks at active gene promoters by
the torsion-based enhancement of nucleosome turnover [19]. Eviction of endogenous and
GFP-tagged histones (H2A, H2B, H3 and H4) from chromatin occurs at�9 μM Dox, overlap-
ping the peak concentrations of the drug observed in the plasma of patients undergoing Dox
therapy [13]. Daunomycin, another anthracycline drug, also induces release of the H1 and
H2B histones from the chromatin and aggregation of the latter in live cells at clinically relevant
concentrations [20].
Antracycline induced chromatin aggregation was initially described using analytical ultra-
centrifuge analysis, equilibrium dialysis and circular dichroism [21]. The mechanism of aggre-
gation was suggested to involve intercalation of the drug to the linker DNA causing
unwinding of the double-helix, followed by the release of the H1 linker histones [20,22], what
would result in an unfolded chromatin conformation and aggregation due to histone-DNA
interfiber interactions [11,23]. Morphological changes were observed in the fluorescent micro-
scope upon anthracycline treatment of cells harboring fluorescent protein-tagged histones that
were interpreted in terms of chromatin aggregation [20]. Relocation of H1 to nucleoli was also
observed in the same study [20]. The appearance of H1 in the cytoplasm of dendritic cells
(DCs) upon activation [24] was also reported. Anthracycline-induced aggregation of H2A
(rather than of chromatin) and the nucleo-cytoplasmic translocation of H2B, demonstrated
herein in live cells, have not been described earlier to our knowledge.
We have developed a Laser Scanning Cytometry (LSC)-based method to quantitatively
assess histone aggregation and studied redistribution of the evicted histones by confocal laser
scanning microscopy (CLSM), as well as mass spectrometry (MS). We report here a global and
differential aggregation/redistribution of the two members of the histone dimer upon Dox
treatment of Jurkat and human peripheral blood mononuclear cells (hPBMCs), as well as in
monocyte-derived DCs.
Results
Marked aggregation of H2A but not of H2B induced by Dox treatment
We detected intranuclear aggregation of H2A, but not of H2B histones, in Jurkat cells after
treatment with Dox, using a LSC-based procedure shown in Fig 1A. The agarose-embedded
live Jurkat cells were treated with 0–36 μM Dox for 2 hrs, then either fixed (pre-fixation) and
subsequently permeabilized by the Triton X-100-containing lysing solution, or treated with
this solution without previous fixation (as described in Materials and Methods). Our interpre-
tation of the aggregation dependent redistribution of H2A induced by Dox is shown in Fig 1D.
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Free histones, including those evicted by Dox, could diffuse out of the nuclei and were subse-
quently washed out, while aggregated and/or DNA-bound histones remained in the nuclei and
were labeled by indirect immunofluorescence for subsequent analyses by LSC. The level of
H2A in the nuclei of control cells was much lower than that of the pre-fixed samples, because
the latter contain a pool of free histones readily diffusing out from the nuclei of the Dox-
untreated cells. When sucrose rather than salt was used to set osmolarity, an old practice pre-
serving nuclear morphology [25], the phenomenon was not detectable (Fig 1B). Sucrose, by
increasing viscosity and thereby significantly decreasing diffusion, apparently facilitated
rebinding of the histones evicted by Dox in the time interval prior to fixation and immunoflu-
orescence labeling. After treatment of the cells with Dox, increased amounts of H2A remained
in the nuclei obtained by Triton X-100/PBS-EDTA lysis. Retention was Dox concentration-
dependent, starting below somewhat 9 μM and reaching the H2A levels of the pre-fixed con-
trol nuclei at 36 μM drug concentration. The rise in H2A level somewhat surpassed what was
measured in pre-fixed cells most likely because of the decreased binding of the antibody to the
formaldehyde-fixed antigens. In sharp contrast with H2A, no retention of H2B was detected in
the assay when H2A and H2B were simultaneously measured (Fig 1C). Confocal microscopic
images demonstrating the distribution of H2A retained in the nuclei after Dox treatment are
shown in Fig 1E. The aggregated histones appeared to localize mostly to the space outside the
trabeculate compartment of genomic DNA stained with propidium iodide (PI), corresponding
to aggregated chromatin. No DNA could be detected within the aggregated H2A domains
even at maximal amplification of the DNA signal (S1 Fig).
Massive nucleo-cytoplasmic translocation of endogenous H2B, but not of
H2A, after Dox treatment
As compared to H2A, histone H2B behaved in a sharply different manner upon Dox treatment
not only in terms of aggregation tendency (see Fig 1C), but also in its intracellular localization.
As shown in Fig 2A–2D, H2B accumulated in the cytoplasm in a Dox concentration and time-
dependent manner, forming a gradient with ~3x higher amount of the histone in the cyto-
plasmic compartment relative to the nucleus. H2B nucleo-cytoplasmic translocation, likely an
active process in view of the gradient formed (Fig 2C), started at a Dox concentration as low as
~2 μM. Depletion of H2B from the center of the nucleus occurred already after 15–30 mins of
treatment and propagated to the periphery concomitantly with a gradual elevation of H2B
Fig 1. Marked aggregation of H2A, but not of H2B upon Dox treatment. (A) Cytometric assay of histone
aggregation. Agarose-embedded live Jurkat cells were treated with Dox, then fixed and subsequently permeabilized
(„Pre-fixed”) or lyzed only. H2A or H2B were detected by indirect immunofluorescence and analyzed by LSC. G1 cells
were gated based on the PI distribution histograms. (B) H2A levels after treatment with different concentrations of
Dox, cells lyzed with 1% Triton X-100 in PBS/EDTA after Dox treatment (continuous line), cells pre-fixed and then
permeabilized by the same lysing solution (dashed line), cells lyzed with 1% Triton X-100 in sucrose/EDTA (dash-
dotted line). The symbols represent measured points, while the lines show the best fit as described in Materials and
Methods. LSC settings (photomultiplier voltage gain and offset) were identical during the measurement of all the
samples. (C) H2A (continuous line) and H2B (dashed line) levels after treatment with different concentrations of Dox.
Fluorescence intensities were normalized to the intensity of untreated samples. In (B) and (C) error bars show SEM
values, characterizing population heterogeneity, calculated for the G1 cell population in a representative experiment.
LSC settings were as before. (D) Proposed scheme of Dox-induced aggregation dependent H2A retention. In the
permeabilized nuclei, free H2A molecules diffuse out before immunofluorescence labeling, while aggregated and
chromatin bound histones remain inside the nuclei. (E) Confocal microscopic images of cells treated with 36 μM Dox
and of control cells. After fixation, H2A was detected by immunofluorescence (green) and DNA by PI staining (red).
Instrument settings (laser power, photomultiplier voltage, gain, pixel dwell time) and all settings of the image analyses
were identical for the compared samples of this panel. Single channel images and an image with amplified DNA signal
are shown in S1 Fig.
https://doi.org/10.1371/journal.pone.0231223.g001
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detected in the cytoplasm (Fig 2B and 2D). After 2 hrs of Dox treatment, the majority of H2B
was depleted from the nuclei and accumulated in the cytoplasm.
To investigate the possible mechanisms of cytoplasmic H2B accumulation, treatment of the
Jurkat cells with inhibitors of biochemical processes that could perhaps account for the cyto-
plasmic accumulation of H2B were performed (Fig 3). The possible role of an increased de
novo protein synthesis in the accumulation of cytoplasmic H2B was excluded by blocking the
synthetic process with puromycin or cycloheximide. Inhibition of CRM1 mediated nuclear
export by leptomycin B failed to diminish the Dox-induced H2B translocation. The anthracy-
cline-induced histone aggregates may be recognized by the cell as denatured proteins destined
for elimination by degradation and/or export out of the nuclei [26]. Therefore, inhibitors
affecting such pathways were also tested. H2B export could be strongly diminished by PYR-41,
Fig 2. Nucleo-cytoplasmic translocation of endogenous H2B after Dox treatment. (A) Dox concentration dependence of H2B nucleo-cytoplasmic translocation. H2B
was detected by immunofluorescence (green), DNA was stained with PI (red) in the fixed Jurkat cells. Representative confocal microscopic images are shown. For single
channel images see S2 Fig. (B) Time dependence of Dox-induced H2B nucleo-cytoplasmic translocation. The yellow and blue arrows show depletion of H2B from the
central and peripheral nuclear regions, respectively. Control cells incubated in the absence of Dox or labeled only with secondary antibody are also shown. Staining of H2B
and of DNA were as in (A). Instrument settings (laser power, photomultiplier voltage, gain, pixel dwell time) and settings of image analyses performed by ImageJ were
adjusted so as to detect also cytoplasmic H2B in the control cells and were identical for each compared sample of a particular experiment, both in the case of panel A and
B. For single channel images see S2 Fig. (C), (D) Quantification of fluorescence microscopic images of panel A and B, respectively. The total cytoplasmic H2B
immunofluorescence was determined as described in Materials and Methods and normalized to the total cellular immunofluorescence. Error bars represent SEM.
https://doi.org/10.1371/journal.pone.0231223.g002
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Fig 3. Effect of various inhibitors on Dox-induced H2B nucleo-cytoplasmic translocation. (A) The cells co-treated with the drug(s) indicated in the Figure and with
36 μM Dox for 2 hrs were fixed and stained as in Fig 1E. H2B was labeled with a monoclonal anti-H2B antibody, except for the samples marked with an asterisk (�) that
were labeled with a polyclonal anti-H2B antibody (see Materials and Methods). # marks the sample treated with both 50 μM PYR-41 and 100 μM 2-D08 (upper image),
or co-treated with the two inhibitors and 36 μM Dox (lower image). DNA was stained with PI. H2B immunofluorescence: green; PI: red. Representative confocal
microscopic images are shown. Instrument settings and settings of image analyses performed by ImageJ were identical for each compared sample of a particular
experiment. Single channel images are shown in S3 Fig. (B) Quantification of fluorescence microscopic images of panel A. The total cytoplasmic H2B
immunofluorescence was determined as described in Materials and Methods and normalized to the total cellular immunofluorescence. Error bars represent SEM. �
indicates significant difference based on two-tailed Student’s t-test (p<0.001).
https://doi.org/10.1371/journal.pone.0231223.g003
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an inhibitor of diverse processes including E1-mediated ubiquitination [27]. After co-treat-
ment with Dox and PYR-41, H2B showed a characteristic nuclear localization pattern with
spatial separation of the histone and the DNA-containing chromatin, reminiscent of the segre-
gation of H2A from chromatin after Dox treatment alone. Dox-induced H2B export could not
be reduced by another ubiquitination inhibitor MLN7243, the NEDDylation inhibitor
MLN4924 or the SUMOylation inhibitor 2-D08. Co-treatment with 2-D08 partially attenuated
the effect of PYR-41 on Dox-induced H2B translocation, leading to a moderate cytoplasmic
accumulation of H2B upon Dox treatment. Neither inhibitors of transcription (α-amanitin or
actinomycin D), nor an inhibitor of Hsp90 (17-AAG) were able to revert the Dox-induced
H2B export. H2B cytoplasmic accumulation was detected using two different (monoclonal vs.
polyclonal) anti-H2B antibodies. Both commercially available antibodies are extensively used
to visualize H2B with high specificity and sensitivity [28–30]. Nonspecific binding of the sec-
ondary antibody was ruled out by incubating the cells with the secondary antibody only (see
Fig 2).
We investigated cytoplasmic H2B relocation also in primary human lymphoid cells. As Fig
4 demonstrates, Dox treatment elicited cytoplasmic relocation of H2B in human peripheral
blood mononuclear cells (hPBMCs). In further similarity with the effects demonstrated in Jur-
kat cells, Dox caused no translocation of H2A in hPBMC nuclei but induced its segregation
from chromatin that exhibited a trabeculate staining pattern. H2B translocation was overruled
by PYR-41 treatment also in these cells, when the histone accumulated between the DNA-con-
taining chromatin domains.
In view of the involvement of extranuclear H2B in innate immunity [31–34], we tested the
effect of Dox on the distribution of this histone in monocyte-derived human DCs. Similarly to
the other cells studied, Dox triggered a near-complete eviction of H2B from the nuclei, what
was reverted by PYR-41, as shown in Fig 5. H2B was present in the cytoplasm of these cells at a
surprisingly high level even in the absence of any treatment.
The Dox-induced nucleo-cytoplasmic H2B export was confirmed using mass spectrometric
(MS) analyzes of supernatants of the cytoplasmic cell lysates, performed in parallel with the
microscopic assessment of H2B remaining in the nuclei (S8 Fig). MS analysis showed an ele-
vated H2B content in the supernatant of Dox-treated lyzed cells, simultaneously with the van-
ishing of the histone from the nuclei, as compared to the untreated control.
The MS analyses also showed that a number of other histones (Table 1) and nuclear pro-
teins (Table 2) were released from the nuclei by Dox. Under these experimental conditions, i.e.
upon lysis of the cytoplasmic content by Triton X-100 and following centrifugation, increased
amounts of other histones, prominently H1.2, was also detected in the supernatant of Dox-
treated cells. However, only the appearance of H2B in the supernatant was PYR-41-sensitive.
A series of non-histone proteins also exhibited increased elution from the nuclei upon Dox
treatment under these conditions (Table 2). Both the magnitude of the Dox-induced protein
release from the nucleus and their PYR-41-sensitivity varied greatly among the non-histone
nuclear proteins as well.
We investigated the possibility if the cytoplasmic presence of H2B is the result of decreased
cell viability. As Fig 6A demonstrates, the Dox-treated cells showed neither PI uptake nor an
increased Annexin V binding after the 2 hrs of Dox treatment. (The red signal was somewhat
upshifted in the Dox-treated samples since the fluorescence emission of the drug partially
overlaps with the emission spectrum of PI using the filter set described in Materials and Meth-
ods.) The impression that histone aggregation and relocation were not the result of cytotoxicity
manifesting at the end of 2 hrs of Dox treatment was also confirmed by the fact that the degree
of H2A retention was not sensitive to the caspase inhibitor Z-VAD-FMK (S5 Fig). Dox con-
centration dependent toxicity was detected by the resazurin assay 24 hrs after Dox treatment
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(see Fig 6C). According to the normalized isobologram in Fig 6D, Dox and PYR-41 (the agent
that reversed Dox-induced H2B translocation; see Fig 3) were cytotoxic in a synergistic man-
ner, suggesting that H2B accumulation in the cytoplasm may not significantly contribute to
long-term toxicity. Indeed, cell proliferation was inhibited by 2 hrs of Dox treatment also in
the case of co-treatment with PYR-41 as measured by the CellVue dye-dilution assay after 2
days, based on the fact that the corresponding distribution histograms have similar medians
(Fig 6B; magenta and grey lines).
Discussion
Dox treatment induced a marked nuclear aggregation of H2A, as opposed to H2B, at therapeu-
tically relevant concentrations (Fig 1B and 1C). Chromatin aggregation upon anthracycline
treatment has been described earlier in in vitro [11,23] and in vivo [20] systems. This is the
first report to our knowledge describing such phenomena involving histones alone. Histones
are known to be evicted from the chromatin by Dox in an intercalator concentration
Fig 4. Nucleo-cytoplasmic translocation of H2B but not of H2A, and histone aggregation after Dox treatment of hPBMCs. (A) Upper row: Dox concentration
dependence of H2B nucleo-cytoplasmic translocation. Lower row: H2A immunofluorescence in the same cells that are shown in the upper row. The cells were
treated with Dox alone or with Dox and 50 μM PYR-41 together for 2 hrs. DNA was stained with PI. The colors are as in the previous Figures. Representative
confocal microscopic images are shown. Instrument settings and settings of image analyses performed by ImageJ were identical for each compared sample of a
particular experiment. Single channel images are included in S4 Fig. (B) Quantification of fluorescence microscopic images of panel A. The total cytoplasmic H2B
immunofluorescence was determined as described in Materials and Methods and normalized to the total cellular immunofluorescence. Error bars represent SEM.�
indicates significant difference based on the two-tailed Student’s t-test (p<0.001).
https://doi.org/10.1371/journal.pone.0231223.g004
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dependent manner (see [13,15,20,23]). Through the spectacles of confocal microscopy the
majority of H2A molecules detected by immunofluorescence becomes topologically separated
from the DNA-containing regions upon treatment with>9 μM Dox and gets trapped inside
the nuclei as measured in our LSC-based assay (Fig 1, S1 Fig). Thus, the nuclear consequences
of Dox treatment are the composite result of eviction and aggregation rather than of eviction
alone.
Fig 5. Effect of Dox and PYR-41 on the levels of H2B histones detected in the cytoplasm of DCs. (A) Cells treated with the drug(s) indicated in the Figure for 2
hrs were fixed and labeled with a monoclonal anti-H2B antibody (green) and the DNA was stained by PI (red). Representative confocal microscopic images are
shown. Instrument settings and settings of image analyses performed by ImageJ were identical for each compared sample of a particular experiment. More images
are shown in S9 Fig. (B) Quantification of fluorescence microscopic images of panel A. The total nuclear H2B immunofluorescence was determined as described
in Materials and Methods and normalized to the total cellular immunofluorescence. Error bars represent SEM.� indicates significant difference based on the two-
tailed Student’s t-test (p<0.001).
https://doi.org/10.1371/journal.pone.0231223.g005
Table 1. Histones detected by MS in the supernatant of Dox-treated, Dox + PYR-41-treated and untreated samples.
Histone Protein name Control Dox Dox + PYR-41 Fold change (Dox/Control) Fold change (Dox + PYR-41/Control)
H1.2 Histone H1.2 7.14E-04 5.24E-03 9.80E-03 7.34 13.73
H1.5 Histone H1.5 1.44E-03 3.00E-03 4.08E-03 2.09 2.84
H2A Histone H2A type 1-J 1.39E-03 4.37E-03 2.63E-03 3.15 1.90
H2B HIST1H2BC 2.06E-03 4.17E-03 2.44E-04 2.02 0.12
H4 HIST1H4A 1.64E-03 3.95E-03 1.98E-03 2.41 1.21
The values represent ratios of the histone specific molecular fragments relative to the internal standard. Fold changes induced by Dox and by Dox + PYR-41 were
calculated as the ratio of proteins detected in the supernatants of drug-treated and control samples. Dox-treated cells: Dox; Dox+PYR-41-treated cells: Dox+PYR-41;
untreated cells: Control.
https://doi.org/10.1371/journal.pone.0231223.t001
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H2B also appeared to be segregated from the DNA-containing chromatin compartment
when its exodus to the cytoplasm was prevented by PYR-41 co-treatment (Figs 3 and 4). Since
aggregation was not detectable in our LSC-assay (S6 Fig), the composition, size and/or stability
of the aggregates (formed in the presence of PYR-41) may be different from that of the H2A
aggregates. The fact that H2A and H2B can be separated by HPLC, implying a difference in
the overall hydrophobicity of the two histones [35], is in line with their differential aggregation
tendencies upon Dox treatment, what may be due to different amounts of the drug bound to
the two histones. The two members of the dimer can be released from the tetrasomes indepen-
dently from each other (see S13 Fig of ref. [15]), so they could also be independently affected
Table 2. Examples of non-histone proteins detected by MS in the supernatants of Dox-treated, Dox + PYR-41 co-treated and control samples.
Protein function Increased
fraction
Examples Fold change
(Dox)
Fold change (Dox + PYR-
41)
Chromatin architecture 9/9 Isoform 2 of Nucleosome assembly protein 1-like 1 6.70 2.81
Regulator of chromosome condensation 2, isoform
CRA_a
4.42 3.79
Isoform 2 of Histone deacetylase 2 1.68 0.79
Histone acetyltransferase type B catalytic subunit 6.10 4.52
Lamina-associated polypeptide 2, isoforms beta/gamma 2.80 2.60
Transcription / RNP / Splicing 32/34 U5 small nuclear ribonucleoprotein 200 kDa 3.32 0.54
Heterogeneous nuclear ribonucleoprotein K, isoform
CRA_d
2.39 1.87
Pre-mRNA-processing factor 19 5.96 3.39
RNA transcription, translation and transport factor
protein
2.01 1.27
Isoform 3 of 60 kDa SS-A/Ro ribonucleoprotein 2.36 2.08
Replication / Repair 20/20 RuvB-like helicase (Fragment) 3.11 1.23
DNA helicase 2.28 2.42
Poly [ADP-ribose] polymerase 1 2.70 2.07
DNA-dependent protein kinase catalytic subunit 2.83 1.41
DNA replication licensing factor MCM6 2.72 2.84
Nuclear Import / Export 8/8 Importin-7 2.78 0.52
GTP-binding nuclear protein Ran 2.98 2.46
Importin-5 2.35 2.24
Importin subunit beta-1 OS 3.19 3.55
Exportin-1 1.36 1.12
Ubiquitination / Proteasome /
SUMOylation
32/34 Proteasome subunit alpha type 2.72 0.63
SUMO-activating enzyme subunit 2 2.52 2.40
SUMO-activating enzyme subunit 1 1.60 2.26
Polyubiquitin-B (Fragment) 3.54 4.25
Proteasome activator complex subunit 2 2.00 2.11
Heat Shock Proteins 4/5 Heat shock 60kDa protein 1 (Chaperonin), isoform
CRA_a
2.25 2.53
Heat shock protein HSP 90-beta 2.51 2.58
Heat shock 70 kDa protein 4 2.71 2.71
Isoform Beta of Heat shock protein 105 kDa 2.34 2.16
Fold change was calculated as in Table 1. Increased fraction in the functional categories designates the ratio of the number of different proteins with elevated levels in
the supernatant (fold change (Dox) > 1) and the total number of identified proteins in that functional group. Proteins exhibiting reversal of the Dox-effect by PYR-41
are shown in italics.
https://doi.org/10.1371/journal.pone.0231223.t002
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by Dox treatment. In the absence of PYR-41 H2B probably escapes aggregation because of its
disappearance from the nuclei.
Dox caused a massive increase of cytoplasmic H2B, but not of H2A levels (Figs 3 and 4).
The cytoplasmic accumulation of H2B upon Dox treatment is a phenomenon not described
before for any of the histones to our knowledge. This is to be taken into account among the
responses of cells to Dox treatment in view of the small concentration of Dox required for the
effect, what was detected in Jurkat cells, hPBMCs as well as DCs. The fact that H2B accumu-
lated in a trabecular pattern outside the DNA-containing compartment in the samples co-
treated with PYR-41 (Figs 3 and 4) shows that the dissociation of the histone from chromatin
induced by Dox was not affected, i.e. just the export of H2B was inhibited by PYR-41. The con-
comitant accumulation of H2B in the cytoplasm was detected by immunofluorescence, using
either a monoclonal or a polyclonal antibody (Fig 2C and 2D), and it was observed in the MS
experiment (S8 Fig) as well, where it also exhibited PYR-41 sensitivity. The fact that H2B could
be detected by the same antibodies in the nucleus in PYR-41 co-treated cells (Fig 3) is also
taken as evidence for the specificity of immunofluorescence detection. Although anthracy-
cline-induced intranuclear (nucleolar) H1 relocation was readily detected using GFP-tagged
H1 expressor cells [20], we observed no nucleo-cytoplasmic export of H2B-GFP (S7 Fig). The
difference between the re-location of H2B, as detected by immunofluorescence, and the lack of
Fig 6. Early and late effects of Dox treatment on the viability of Jurkat cells. (A) Viability assessed immediately after 2 hrs of treatment with 36 μM Dox
as compared to that of the control cells. The scatterplots show Annexin V-FITC and PI staining of G1 gated cells. (B) CellVue dye-dilution cell proliferation
assay of Dox and Dox + 6 μM PYR-41 co-treated Jurkat cells (see Materials and Methods). Far red fluorescence intensity distributions were recorded at 2
hrs and at 48 hrs after addition of the drugs. PI positive cells were excluded from the analyses. (C) Dose-Effect Curve for Dox and PYR-41 based on
resazurin assay performed 24 hrs after the 2 hrs Dox treatment. (D) Normalized Isobologram of Dox + PYR-41 co-treatment, using 50μM PYR-41 and
Dox applied in a concentration range of 2.25–72 μM. In this representation the data points below or above the line indicate synergistic or antagonistic drug
interactions, respectively; see Materials and Methods.
https://doi.org/10.1371/journal.pone.0231223.g006
PLOS ONE Doxorubicin induces H2A and H2B redistribution
PLOS ONE | https://doi.org/10.1371/journal.pone.0231223 April 16, 2020 11 / 23
it in the case of H2B-GFP, was clearly demonstrated when both entities were visualized at the
same time (S7 Fig). The interference of the GFP tag with nucleo-cytoplasmic translocation is
in line with the involvement of a specific transport mechanism and may not be surprising in
view of the fact that even a Flag tag can have profound effects on the molecular interactions
involving H2B [36].
Highly reduced intranuclear H2B content along with highly increased cytoplasmic H2B lev-
els upon Dox treatment (Figs 2C, 2D, 4B and 5) can be explained by the presence of an active
export mechanism and intact nuclear membranes, the latter serving as a barrier impeding
H2B nuclear re-entry. In contrast with its complete reversal effected by PYR-41, cytoplasmic
accumulation of H2B was not significantly altered by inhibiting CRM1-dependent nuclear
export, or applying inhibitors of ubiquitination, NEDDylation, SUMOylation, transcription,
protein synthesis or Hsp90 function (Fig 3). PYR-41 acts mainly as an inhibitor of the ubiqui-
tin-activating enzyme (E1), with little or no effect on the ubiquitin-conjugating enzyme (E2)
[27]. However, the agent was also shown to enhance total SUMOylation in cells [27]. Induc-
tion of non-specific protein cross-linking may also contribute to its toxicity [37]. Furthermore,
it seems to be also a deubiquitinase (DUB) inhibitor [37]. The other inhibitor of E1-mediated
ubiquitination tested herein did not reproduce the effect of PYR-41, and the combined treat-
ment with 2-D08 SUMOylation inhibitor mitigated the PYR-41-elicited reversal of cyto-
plasmic H2B accumulation following Dox treatment (when H2B was present at high levels
both in the cytoplasm and in the nucleus; see Fig 3). Thus we assume that H2B export may be
connected to the biochemical circuitry controlling protein degradation via the ubiquitin-like
posttranslational modification, SUMO. The main nuclear export pathway is CRM1 (also
known as exportin-1 or XPO1) dependent, which can be inhibited by leptomycin B that alkyl-
ates and inhibits the CRM1 protein [38]. The insensitivity of H2B translocation to even high
concentrations of this agent argues against the involvement of this mechanism. Several CRM1
independent nuclear export pathways have been described, including the transport of mature
mRNAs [39,40], of poly(A)+ RNAs [41] and RNA helicases [42]. Biochemical processes involv-
ing SUMOylation are important determinants of nuclear export of mRNAs [43] and proteins
[44]. H2B translocation from the nucleus to the cytoplasm further increases the plethora of
molecular events that are to be considered as components of Dox toxicity.
The likely involvement of protein degradation-related pathways in Dox-induced H2B
nucleo-cytoplasmic export (Figs 3 and 4) raises the possibility that the phenomenon may have
relevance in connection with the following published observations: Enhanced protein degrada-
tion may play an important role in the acute cardiotoxicity of Dox therapy [45]; down-regula-
tion of UBC9, an E2-conjugating enzyme that is required for SUMOylation, increases the
sensitivity of hepatocellular carcinoma to Dox [46]; the SUMO pathway is a major determi-
nant of Dox cytotoxicity in yeast [47]; down-regulation of histone H2A and H2B pathways is
associated with anthracycline sensitivity in breast cancer [48]. It will be interesting to elucidate
the exact relationship between the protein degradation-related pathways and H2B cytoplasmic
accumulation to investigate the above possible links.
The nucleo-cytoplasmic translocation of H2B induced by Dox may be connected to H2B
export occurring in certain physiological and pathological circumstances. Instances of extra-
nuclear location of histones have been documented [49,50]. Extracellular histones can function
as microbicidal proteins [34], on the other hand histones released in sepsis contribute to endo-
thelial dysfunction [51]. Apoptosis unrelated nucleo-cytoplasmic translocation of H1 histone
was detected in HeLa cells [52], and extrachromosomal H2B is known to mediate innate anti-
viral immune responses [31,32,53]. Remarkably, H2B in complex with gamma-interferon-
inducible protein 16 was shown to be present in the cytoplasm during Epstein-Barr Virus and
Herpes Simplex Virus-1 infection in non-apoptotic cells [33]. Dox treatment evoked a PYR-41
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sensitive nucleo-cytoplasmic translocation of H2B also in DCs, similarly to Jurkat and
hPBMCs, resulting in significantly decreased intranuclear H2B levels. Intriguingly, DCs
exhibit high cytoplasmic levels of H2B in the absence of any treatment (Fig 5), especially in
plasma membrane proximal areas. Since macrophages and DCs are the frontline cells of innate
immunity [54], it is possible that the elevated cytoplasmic H2B levels in DCs are required for
pattern recognition (Fig 5) [55]. The fact that the cytoplasmic levels of H2B can be readily
increased by treatment with >2 μM Dox (Fig 2) raises the intriguing possibility that the H2B-
related pathways of antiviral and antimicrobial immune response may be boosted by Dox
treatment.
As Tables 1 and 2 show, Dox treatment facilitated the release of a wide variety of nuclear
proteins. The proteins exhibiting enhanced release from the nucleus upon Dox treatment
(Table 2) are very diverse, suggesting that the entire nuclear structure is affected by the drug.
This Dox-induced effect is apparently superimposed on a background of non-specific release
of nuclear proteins likely explained by the conditions required in the MS experiment. These
include non-ionic detergent treatment as well as centrifugation of the nuclei with concomitant
mechanical stress, i.e. steps that are absent when agarose-embedded live cells are treated with
the anthracycline, fixed with 4% FA and processed for immunofluorescence detection. This
experimental scenario apparently facilitated the discharge of proteins from the nucleus, dem-
onstrated by the fact that Dox-aggregated H2A, shown not to be translocated to the cytoplasm
under the less-perturbed conditions required by immunofluorescence detection (Figs 3, 4 and
5), also appeared in the supernatant of the Dox-treated samples (S8 Fig). Importantly, the
appearance of H2A in the supernatant was much less PYR-41 sensitive than that of H2B in
these conditions (Table 1). Destabilization of various other histones and an array of proteins
involved in the organization of chromatin architecture, in transcription, splicing, replication,
repair, nuclear export and import, in heat shock and those involved in protein degradation
was observed upon Dox treatment, some of which also exhibited PYR-41-sensitive response to
the drug (Tables 1 and 2). These Dox-induced perturbations of intermolecular interactions in
the nucleus may all contribute to the effects and side-effects of anthracyclines observed in the
clinical practice.
The fact that there was no toxicity detected at 2 hrs after addition of Dox (Fig 6A), shows
that redistribution of the histones occurs in live cells. H2A aggregation ensues at�10 μM Dox,
giving rise to ~50% toxicity at 24 hrs (Fig 6C) and an impact on cell proliferation detectable
after 48 hrs (Fig 6B), i.e. aggregation measured at 2 hrs may be predictive of long-term toxicity
and could be exploited as its convenient indicator. H2B translocation may be an even more
sensitive predictor as it can be observed already at ~2 μM Dox concentration, resulting in
~15–20% cytotoxicity at 24 hrs.
We speculate that the nucleo-cytoplasmic export of H2B, which is impeded by PYR-41,
may be a protective pathway rescuing cells from the toxic effect of intranuclear histone aggre-
gation. This scenario appears to be supported by the fact that co-treatment with PYR-41 and
Dox exhibited a strongly synergistic cytotoxic effect, not merely additivity (Fig 6D). The
observed synergy raises the possibility that combined administration of Dox and PYR-41 may
be exploited in cancer chemotherapy, since PYR-41 is already considered as a potential anti-
cancer agent [27]. Interestingly, PYR-41 also mitigates lung injury in sepsis by targeting the
NF-κB pathway involved in the inflammatory response to circulating histones in septic condi-
tions [51,56].
The reported range of peak plasma concentrations of Dox is rather wide: values between 0.5
and 9 μM have been reported [13,57–60]. Therefore, the Dox concentration range used in our
experiments and the peak plasma concentrations in clinical settings could overlap. The cyto-
toxicity of many DNA-binding small molecules seems to correlate more with their ability to
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cause chromatin damage than with DNA damage [61]. Our observations expand the list of
molecular changes supporting such a scenario, raising the possibility that the severe perturba-
tions in H2A and H2B intracellular and intranuclear localization observed may be of interest
also from the medical point-of-view, regarding both the effects and side-effects of anthracy-
cline treatment. It will be intriguing to test if the novel phenomenon of Dox-induced H2B
nucleo-cytoplasmic export may be exploited to boost or modulate immune response involving
extrachromosomal H2B [31,32,53]. Aggregation of H2A may be a manifestation of the general
protein aggregating effect of Dox, detected also in yeast [62] and considered to significantly
contribute to the cardiotoxicity of this agent [63]. The LSC-based assay of H2A aggregation
described herein may find its application also in studies addressing various other cell biological
conditions involving protein aggregation in the nucleus.
Materials and methods
Cell culture
Jurkat cells were grown in T150 tissue culture flasks (Corning Glass Works, Corning, NY)
using RPMI-1640 (Gibco, Grand Island, NY) and 10% fetal bovine serum. The cultures con-
tained penicillin (100 μg/ml), streptomycin (0.25 μg/ml), and glutamine to a final concentra-
tion of 2 mM.
hPBMCs and human monocyte-derived DC cultures. Leukocyte-enriched buffy coats
were obtained from healthy blood donors drawn at the Regional Blood Center of the Hungar-
ian National Blood Transfusion Service (Debrecen, Hungary) in accordance with the written
approval of the Director of the National Blood Transfusion Service of the University of Debre-
cen, Faculty of Medicine (Hungary) and from the Regional and Institutional Research Ethical
Committee of the University of Debrecen. Written, informed consent was obtained from the
blood donors prior to blood donation, their data were processed and stored according to the
directives of the European Union. hPBMCs were separated by a standard density gradient cen-
trifugation with Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden). Monocytes
were purified from hPBMCs by positive selection using immunomagnetic cell separation and
anti-CD14 microbeads, according to the manufacturer’s instruction (MiltenyiBiotec, Bergisch
Gladbach, Germany). After separation on a VarioMACS magnet, 96–99% of the cells were
shown to be CD14+ monocytes, as measured by flow cytometry. Isolated monocytes were
plated at 1 x 106 cell/ml concentration in AIM-V medium (Gibco, Paisley, Scotland) contain-
ing L-glutamine and supplemented by 1% Gentamicin/Streptomycin solution (Hyclone, South
Logan, Utah) in the presence of 100 ng/ml IL-4 (Peprotech EC, London, UK) and 80 ng/ml
GM-CSF (Gentaur Molecular Products, Brussels, Belgium) added on day 0 and 2. Monocytes
were cultured for five days in 24-well tissue culture plates.
Embedding live cells into low melting point agarose
Embedding was carried out according to Imre et al. [15]. Briefly, the wells of 8-well chambers
(Ibidi, Martinsried, Germany) were coated with 1% (m/v) low melting point (LMP) Agarose.
The cell suspension containing 6 x 106 cells/ml of PBS was mixed with 1% LMP agarose diluted
in 1 x PBS at 37˚C, and the cell-agarose suspension was dispensed in the middle of the wells.
After polymerization of the agarose on ice, complete culture medium was added to each well.
Sample preparation for mass spectrometry
Lysis of the 36 μM Dox-treated and control cells was by mixing 0.8 ml of cell suspension con-
taining 2 x 107 cells/ml with 0.2 ml ice cold PBS containing 1% Triton X-100 on ice. After
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incubation on ice for 10 minutes, 14 ml of PBS was added in order to terminate lysis, then the
nuclei were centrifuged at 550 g for 5 minutes. The supernatant was concentrated using Ami-
con Ultra 0.5 ml Centrifugal Filters (EMD Millipore, Darmstadt, Germany), then sent for
Mass Spectrometry. The nuclei were fixed by incubating the pellet in freshly prepared 4%
formaldehyde dissolved in PBS/EDTA, for 10 minutes, then embedded into agarose in 8-well
chambers (Ibidi, Martinsried, Germany) as described above.
Protein concentration of the samples was determined by the Bradford method. Samples
were purified on a 5% SDS-polyacrylamide gel using 80V current for 15 minutes. The proteins
were stained with Coomassie dye. The proteins were excised from the gel and subjected to in-
gel trypsin digestion. Reduction was performed using 20 mM dithiothreitol for one hour at
56˚C followed by alkylation with 55 mM iodoacetamide for 45 minutes. Overnight trypsin
digestion was carried out using stabilized MS grade TPCK-treated bovine trypsin (ABSciex) at
37˚C. Thereafter the digested peptides were extracted and lyophilized. The peptides were re-
dissolved in 10μl 1% formic acid before LC-MS/MS analysis. Prior to LC-MS analysis the sam-
ples were spiked with equal amount of indexed retention time (iRT) peptide mixtures (Biog-
nosys) and the samples were analyzed in duplicates.
LC-MS analysis
Before mass spectrometric analyzes, peptides were separated on a 180 minute water/acetoni-
trile gradient using an Easy nLC 1200 nano UPLC (Thermo Scientific, Waltham, MA, USA).
The peptide mixture was desalted on an Acclaim PepMap 100 C18 trap column (20 x 75 μm,
3 μm particle size, 100 Å pore size, Thermo Scientific, Waltham, MA, USA), followed by sepa-
ration on Acclaim PepMap RSLC C18 analytical columns (150 mm x 50 μm 2 μm particle size,
100 Å pore size, Thermo Scientific, Waltham, MA, USA). The peptides were separated using a
gradient of 5–7% solvent B over 5 minutes, followed by a rinse to 15% of solvent B over 50
minutes, and then to 35% solvent B over 60 minutes. Thereafter solvent B was increased to
40% over 28 minutes and to 85% over 5 minutes, followed by a 10 minutes rinse to 85% of sol-
vent B, after which the system returned to 5% solvent B in 1 minute for a 16 minutes hold-on.
Solvent A was 0.1% formic acid in LC water; solvent B was 95% acetonitrile containing 0.1%
formic acid. The flow rate was set to 300 nl/min.
Data-dependent analyzes were carried out on an Orbitrap Fusion mass spectrometer
(Thermo Scientific, Waltham, MA, USA). The 14 most abundant multiply charged ions were
selected from each survey MS scan using a scan range of 350–1600 m/z for MS/MS analyzes
(Orbitrap analyzer resolution: 60000, AGC target: 4.0e5, acquired in profile mode). CID frag-
mentation was performed in the linear ion trap with 35% normalized collision energy (AGC
target: 2.0e3, acquired in centroid mode). Dynamic exclusion was enabled during the cycles
(exclusion time: 45 seconds).
Mass spectrometry data analysis
The acquired LC-MS/MS data were used for protein identification and quantification with the
help of MaxQuant 1.6.2.10 software [64] searching against the Human SwissProt database
(release: 2018.08, 558125 sequence entries). Cys carbamidomethylation was set as fixed modifi-
cation, Met oxidation and N-terminal acetylation were set as variable modifications. Maxi-
mum 2 missed cleavage sites were allowed. Proteins were accepted with at least 3 identified
peptides using 1% FDR criteria. Label-free protein quantification was performed with the LFQ
algorithm of the MaxQuant software [65]. For data evaluation, the LFQ values of the identified
proteins were normalized to the LFQ values of the iRT mixture, relative amount of proteins
was calculated and indicated in Table 1.
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The H2A and H2B histones remaining in the nuclei were labeled by immunofluorescence.
These intensities and the proteins levels measured in the supernatant by mass spectrometry
were compared on the same scale (see S8 Fig), based on the assumptions expressed by the
equations:
H2A  CTRLðnÞ þ a � H2A  CTRLðsnÞ ¼ H2A  CTRLðtÞ
H2A  DoxðnÞ þ a � H2A  DoxðsnÞ ¼ H2A  DoxðtÞ
H2B  CTRLðnÞ þ a � H2B  CTRLðsnÞ ¼ H2B  CTRLðtÞ
H2B  DoxðnÞ þ a � H2B  DoxðsnÞ ¼ H2B  DoxðtÞ;
to yield a:
a ¼ ½H2A  CTRLðnÞ  H2A  DoxðnÞ�=½H2A  DoxðsnÞ  H2A  CTRLðsnÞ�;
where a is a constant used to convert protein amount measured by MS to fluorescence inten-
sity values measured by LSC. In the equations, sn, n and t designate supernatant, nuclear and
total, respectively. S8 Fig was constructed by plotting the amounts of H2A and H2B detected
in the supernatant and that remaining in the nuclei, in %.
Drug treatments
Doxorubicin, puromycin, cycloheximide, leptomycin B, PYR-41, α-amanitin, actinomycin D,
2-D08 (all Sigma, Budapest, Hungary), 17-AAG (Reagents Direct, Encinitas, USA), MLN4924
(EMD Millipore, Darmstadt, Germany) and MLN7243 (Chemgood, Glen Allen, USA) were
diluted to the final concentrations indicated in the Figures and added to live cells in complete
DMEM medium for the time indicated, prior to fixing and lysis.
Preparation of nuclei
The agarose-embedded cells at the bottom of the wells were washed with 500 μl ice cold 1 x
PBS, three times for three minutes, then lysis/permeabilization was carried out: (I) Samples
were pre-fixed with 400 μl ice cold 4% (m/m) formaldehyde dissolved in 1 x PBS/EDTA on ice
for 15 minutes and subsequently permeabilized by replacing the fixative with 500 μl ice cold
1% (v/v) Triton X-100 dissolved in 1 x PBS/EDTA (5 mM EDTA in PBS), for 10 minutes; (II)
Samples were lyzed with ice cold 1% (v/v) Triton X-100 dissolved in 1 x PBS/EDTA; (III) Sam-
ples were lyzed with 500 μl ice cold 1% (v/v) Triton X-100 dissolved in 300 mM sucrose, 5 mM
EDTA. The lysis/permeabilization step was repeated once more, then nuclei were washed with
500 μl ice cold 1 x PBS/EDTA 3x, for three min each.
Immunofluorescence labeling
After lysis/permeabilization the samples were incubated with 500 μl 5% (m/v) Blotto Non-Fat
Dry Milk (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) in 1 x PBS/EDTA for
30 minutes on ice, to decrease non-specific binding of the antibodies. The blocking solution
was washed out with 500 μl ice cold 1 x PBS/EDTA three times for three minutes and indirect
immunofluorescence labeling was performed using mouse monoclonal anti-H2B (ab52484,
Abcam, Cambridge, UK; 1 mg/ml), rabbit polyclonal anti-H2B (Sigma-Aldrich; 1 mg/ml) or
rabbit polyclonal anti-H2A (ab18255, Abcam, Cambridge, UK; 1 mg/ml). Primary antibodies,
all diluted in 150 μl of 1 x PBS/EDTA/1% BSA (1 x PBS/ EDTA supplemented with 1% w/v
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bovine serum albumin), at 4˚C, overnight. All the above antibodies were applied to the wells at
a titer of 1:800. After labeling with the primary antibodies, the nuclei were washed with 500 μl
ice cold 1 x PBS/EDTA three times for 10 minutes. Labeling with the secondary antibodies was
performed in 150 μl 1 x PBS/EDTA for 2 hrs on ice, using Alexa fluor 488 (A488) or Alexa
fluor 647 (A647) conjugated goat anti-mouse IgG or goat anti-rabbit IgG antibodies (Thermo
Fisher Scientific, Waltham, Massachusetts, USA), with identical results. In the figures shown
H2A was detected by A647 (red channel) and H2B by A488 (green channel). The secondary
antibodies were also used at a titer of 1:800, diluted in 1 x PBS/EDTA from 2 mg/ml stock solu-
tions. After labeling with the secondary antibodies, the agarose-embedded nuclei were washed
with 500 μl ice cold 1 x PBS/EDTA three times for 10 minutes. Then the samples were stained
with 200 μl 12.5 μg/ml PI (dissolved in 1 x PBS/EDTA) for 60 minutes, on ice. The stained
nuclei were washed 3 times with 500 μl ice cold 1 x PBS/EDTA for 3 minutes. Fluorescence
intensity distributions were recorded using an iCys LSC, as described below.
Confocal microscopy
Imaging was carried out with an Olympus FluoView 1000 CLSM equipped with 488 and 633
nm lasers, using a 60x oil immersion oil objective. Composite images were constructed and
evaluated using ImageJ software. Instrument settings (laser power, photomultiplier tube volt-
age, gains, pixel dwell time) and image analyses parameters (brightness, contrast, gamma fac-
tor of ImageJ) were identical in the case of all the samples compared in a particular
experiment. In S1 Fig, the PI signal was overamplified, as stated there, to demonstrate the sepa-
ration of histones and DNA upon Dox treatment. Nuclear H2B content was calculated by
selecting the nuclei on stack images and determining their total H2B fluorescence integral.
Cytoplasmic H2B was calculated by subtracting nuclear from the total intracellular H2B fluo-
rescence integral (8–10 representative cells /sample).
Automated microscopy (LSC)
Automated microscopic imaging was performed using an iCys instrument (iCys1 Research
Imaging Cytometer; CompuCyte, Westwood, Massachusetts, USA). A488 and PI were excited
using a 488 nm Argon ion laser, A647 was excited with a 633 nm HeNe laser. The fluorescence
signals were collected via an UPlan FI 20 x (NA 0.5) objective. A488 was detected through 510/
21 nm and 530/30 nm filters, respectively, while A647 and PI were detected through a 650/LP
nm filter. Each field (comprising 1000 x 768 pixels) was scanned with a step size of 1.5 μm.
Data evaluation and hardware control were performed with the iCys 7.0 software for Windows
XP. Gating of G1 phase nuclei was according to the fluorescence intensity distribution of the
DNA labeled with PI. The integral fluorescence intensity values, representing the summed
fluorescence intensity of all the pixels representing the nuclei, were measured and averaged by
LSC. The symbols represent measured points, while the lines show the best fit calculated as
described below.
Analysis of the curves was by SigmaPlot 12.0, using the ‘Sigmoid 3-parameter’ curve-fitting
subroutine. Curves in Fig 1C, S5 and S6 Figs were normalized to ‘1’ dividing the mean fluores-
cence intensities of G1 nuclei treated with different concentrations of Dox by that of the non-
treated sample before fitting. 200–1000 G1 phase nuclei/well, distinguished based on DNA
content as well as circularity, were analyzed out of the 500–2000 nuclei scanned per well. All
the SEM values indicated in the Figure were calculated from the datapoints of the cell popula-
tion analyzed in a representative experiment.
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Viability tests and isobologram analysis
Viability was measured immediately after Dox treatment by incubating the samples with 2 μg/
ml PI and Annexin V-FITC (MBL, Woburn, England) according to the manufacturer’s
instructions.
Delayed cytotoxicity was measured by the resazurin viability assay. Resazurin (from Sigma-
Aldrich Hungary) stock solution was prepared by dissolving 1 mg of its sodium salt in 1 ml of
sterile PBS and stored at -20˚C. Treatment of Jurkat cells in complete medium with Dox and
PYR-41 was carried out in 24-well plates. Increasing concentrations of Dox (0–72 μM) or
PYR-41 (0–100 μM) alone were used to determine the dose-response curves of the single
agents. For combination treatment, a fixed concentration of PYR-41 (50 μM) and a concentra-
tion series of Dox were applied. Treatments were performed for 2 hrs, when cytotoxicity was
measured based on mitochondrial function using the resazurin based assay [66]. The cells
were mixed with resazurin in colorless RPMI-1640 medium to a final concentration of 18 μM
of resazurin and 20,000 cells per well of the 96-well flat-bottom microplates. The plates were
incubated at 37˚C for 24 h and the fluorescence signals were measured at 530–560/590 nm
using a microplate reader (Synergy H1, BioTek). Viability was expressed as the fraction of fluo-
rescence in the treated samples, as compared to the control. Affected fraction, the input
parameter of isobologram analyses, was calculated by subtracting the viability values from one.
Isobologram analysis was used as a method for identifying the combined effect of multiple
drugs in terms of additive, synergistic, or antagonistic effects. IC50 (the dose of drug causing
50% cytotoxicity) values were determined and a normalized isobologram was created for the
two drugs at their IC50 using CompuSyn ver. 1.0 (ComboSyn Inc., Paramus, NJ, USA). If the
combination data points fall on the hypothenuse, an additive effect is indicated. If the combi-
nation data points fall on the lower left or on the upper right side, synergism or antagonism is
indicated, respectively.
Cell proliferation assay
The CellVueTM NIR780 Cell Labeling Kit was purchased from Thermo Scientific (Waltham,
MA, USA). The dye-dilution cell proliferation assay was carried out according to the manufac-
turer’s directions. Briefly, Jurkat cells were washed once with serum-free medium and re-sus-
pended in Diluent C at 1.8 x 107 cells/ml and the dye was added at 6 μM final concentration.
Labeling was stopped by adding 1 ml of serum to each 1 ml sample. After washing with serum
containing medium to remove any remaining unbound dye, the samples were treated with 2
and 4 μM Dox or co-treated with 2 μM Dox + 6 μM PYR-41 for 2 hrs. The samples were exten-
sively washed and 2.5 μg/ml PI was added prior to flow-cytometric analyses using a Becton
Dickinson FACSAria III Cell Sorter (Becton Dickinson, Mountain View, CA, USA). The Cell-
Vue dye was excited using the 633 nm line of a solid state laser and the emitted light was
detected using a 780/60 band-pass filter. PI fluorescence was measured by excitation at 531 nm
and emission detection using a 660/40 nm band-pass filter. Fluorescence signals were collected
in logarithmic mode and the flow-cytometric data were analyzed by the Flowing Software
(2.5.1 version).
Supporting information
S1 File.
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S1 Fig. (A) Single-channel confocal microscopic images of Fig 1E. (B) B: Cell treated with
36 μM Dox, with the PI signal over-amplified.
(TIF)
S2 Fig. Single channel confocal microscopic images of Fig 2.
(TIF)
S3 Fig. Single channel confocal microscopic images of Fig 3.
(TIF)
S4 Fig. Single channel confocal microscopic images of Fig 4.
(TIF)
S5 Fig. LSC aggregation assay of H2A. H2A levels after treatment with different concentra-
tions of Dox alone (continuous line) or in the presence of 10 μM Z-VAD-FMK (caspase inhib-
itor) (dashed line). Fluorescence intensities were normalized to the intensity of untreated
samples. Error bars show SEM values.
(TIF)
S6 Fig. LSC aggregation assay of H2B. Intranuclear H2B levels after treating live cells with
different concentrations of Dox alone (continuous line) and with Dox in the presence of
50 μM PYR-41 (dashed line). Fluorescence intensities were normalized to the intensity of
untreated samples. Error bars show SEM values.
(TIF)
S7 Fig. Effect of Dox treatment on GFP-tagged and antibody labeled H2B. Representative
confocal microscopic images of Dox treated H2B-GFP (green) expressor cells labeled with
anti-H2B antibody (red).
(TIF)
S8 Fig. Redistribution of H2A and H2B after Dox treatment. Fractions of H2A (panel A)
and H2B (panel B) remaining in the nuclei or detected in the supernatant (indicated by green
and red colors in the chart, respectively). The cell lysates were prepared without agarose-
embedding, the histones were detected by MS in the supernatant and by LSC in the nuclei.
The fractions shown in panels A and B were calculated as described in Materials and Methods.
Representative microscopic images below show the histones remaining in the nuclei in these
experiments.
(TIF)
S9 Fig. Additional single channel and composite images of antibody labeled H2B in DCs
(see Fig 5).
(TIF)
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